ScholarLens Back to search
2023•Unpublished venueOpen access

Supplementary Table from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma

Lora Hamuro, Zheyi Hu, Julie Passarell, Heather Barcomb, Joshua Zhang, Shay Goldstein, Akintunde Bello, Amit Roy, Zhu Li

Open full text 0 citations

Abstract

Supplementary Table from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma

About this research paper

What this paper is about

Supplementary Table from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Supplementary Table from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma

Key concepts: Cabozantinib, Nivolumab, Renal cell carcinoma, Dosing, Medicine, Oncology, Table (database), Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Supplementary Table from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma — Research Paper | ScholarLens